Market Overview

UPDATE: JP Morgan Downgrades GlaxoSmithKline to Underweight; Investments Risk Earnings

Share:
Related GSK
What Pharmaceuticals Spend On Lobbying To Influence Trump
Three Pivotal Phase III Trials To Watch In Biotech
Oramed Now Has a Clear Path to Market With Oral Insulin (GuruFocus)

JP Morgan reduced its rating on GlaxoSmithKline (NYSE: GSK) from Neutral to Underweight as the company's upcoming investment phase puts 2013 earnings at risk.

JP Morgan commented, "With material risk to 2013 earnings, no imminent positive catalysts, and almost no upside to our new PT, we downgrade to Underweight. GSK is entering an investment phase. After reassessing the investment required to execute on the pipeline, already taken for granted by consensus, we now expect Operating margins to contract, rather than expand in 2013, and we now forecast a 2013 Operating margin 200bps below consensus. We see earnings risk in 2013, with material Operating profit and earnings growth unlikely for at least a year further out than is currently forecast by consensus (which expects topline growth and margin expansion in 2013)."

GlaxoSmithKline closed at $46.07 on Tuesday.

Latest Ratings for GSK

DateFirmActionFromTo
Jul 2017CitigroupDowngradesBuyNeutral
Sep 2016PiperJaffrayInitiates Coverage onOverweight
Sep 2016Exane BNP ParibasDowngradesNeutralUnderperform

View More Analyst Ratings for GSK
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (GSK)

View Comments and Join the Discussion!
Loading...
Loading...